Walleye Capital
EIGR

Walleye Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Walleye Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,417
Closed -$353K – 2784
2022
Q1 		$353K Buy
+1,417
New +$224K 0.01% 1212

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's EIGR Position: Q2 2022 in Review

Walleye Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2022, closing a stake of 1,417 shares — an estimated $353K sold.

Walleye Capital first reported a position in EIGR in Q1 2022 and held it in 1 quarter. The position peaked at $353K in Q1 2022. 91 funds tracked by Wall St. Rank hold EIGR as of Q2 2022.

  • Walleye Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Walleye Capital sold 1,417 Eiger BioPharmaceuticals, Inc. shares in Q2 2022, an estimated $353K.
  • Walleye Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2022 and held it in 1 quarter.
  • Walleye Capital's Eiger BioPharmaceuticals, Inc. position peaked at $353K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.